Bilateral visual outcomes and service utilization of patients treated for 3 years with ranibizumab for neovascular age-related macular degeneration

Randhir Chavan1 Eye Infirmary, New Cross Hospital, Royal Wolverhampton Hospitals NHS Trust Wolverhampton, West Midlands, UKCorrespondence[email protected]

Swati Panneerselvam1 Eye Infirmary, New Cross Hospital, Royal Wolverhampton Hospitals NHS Trust Wolverhampton, West Midlands, UK

Parul Adhana1 Eye Infirmary, New Cross Hospital, Royal Wolverhampton Hospitals NHS Trust Wolverhampton, West Midlands, UK

Nirodhini Narendran1 Eye Infirmary, New Cross Hospital, Royal Wolverhampton Hospitals NHS Trust Wolverhampton, West Midlands, UK

Yit Yang1 Eye Infirmary, New Cross Hospital, Royal Wolverhampton Hospitals NHS Trust Wolverhampton, West Midlands, UK;2 Faculty of Life and Health Sciences, Aston University, Birmingham, UK

Pages 717-723 | Published online: 08 Apr 2014

Cite this article
CrossMark

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

References

nice.org.uk [homepage on the Internet]LondonNational Institute for Clinical Excellence2008 [updated May 2012]Ranibizumab and pegaptanib for the treatment of age-related macular degeneration Available from: http://publications.nice.org.uk/ranibizumab-and-pegaptanib-for-the-treatment-of-age-related-macular-degeneration-ta155Accessed May 1, 2012
Google Scholar
BrownDMKaiserPKMichelsMANCHOR Study GroupRanibizumab versus verteporfin for neovascular age-related macular degenerationN Engl J Med2006355141432144417021319
PubMed Web of Science ®Google Scholar
RosenfeldPJBrownDMHeierJSMARINA Study GroupRanibizumab for neovascular age-related macular degenerationN Engl J Med2006355141419143117021318
PubMed Web of Science ®Google Scholar
CATT Research GroupMartinDFMaquireMGYingGSGrunwaldJEFineSLJaffeGJRanibizumab and bevacizumab for neovascular age-related macular degenerationN Engl J Med2011364201897190821526923
PubMed Web of Science ®Google Scholar
IVAN Study InvestigatorsChakravarthyUHardingSPRogersCARanibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trialOphthalmology201211971399141122578446
PubMed Web of Science ®Google Scholar
BusbeeBGHoACBrownDMHARBOR Study GroupTwelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degenerationOphthalmology201312051046105623352196
PubMed Web of Science ®Google Scholar
SingerMAAweCCSaddaSHORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degenerationOphthalmology201211961175118322306121
PubMed Web of Science ®Google Scholar
MunirajuRRamuJSivaprasadSThree-year visual outcome and injection rrequency of intravitreal ranibizumab therapy for neovascular age-related macular degenerationOphthalmologica20132301273323635665
PubMed Web of Science ®Google Scholar
PushpothSSykakisEMerchantKBrowningACGuptaRTalksSJMeasuring the benefit of 4 years of intravitreal ranibizumab treatment for neovascular age-related macular degenerationBr J Ophthalmol201296121469147323001255
PubMed Web of Science ®Google Scholar
RofaghaSBhisitkulRBBoyerDSSaddaSRZhangKSEVEN-UP Study GroupSeven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP)Ophthalmology2013120112292229923642856
PubMed Web of Science ®Google Scholar
RasmussenABlochSBFuchsJA 4-year longitudinal study of 555 patients treated with ranibizumab for neovascular age-related macular degenerationOphthalmology2013120122630263623830760
PubMed Web of Science ®Google Scholar
LalwaniGARosenfeldPJFungAEA variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO StudyAm J Ophthalmol20091481435819376495
PubMed Web of Science ®Google Scholar
ThomasMMousaSSMousaSAComparative effectiveness of aflibercept for the treatment of patients with neovascular age-related macular degenerationClin Ophthalmol2013749550123503202
PubMedGoogle Scholar
Schmidt-ErfurthUKaiserPKKorobelnikJFIntravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studiesOphthalmology2014121119320124084500
PubMed Web of Science ®Google Scholar
Krüger FalkMKempHSørensenTLFour-year treatment results of neovascular age-related macular degeneration with ranibizumab and causes for discontinuation of treatmentAm J Ophthalmol20131551899523022167
PubMed Web of Science ®Google Scholar
FrennessonCINilssonSEA three-year follow-up of ranibizumab treatment of exudative AMD: impact on the outcome of carrying forward the last acuity observation in drop-outsActa Ophthalmol Epub201334
Web of Science ®Google Scholar
RossAHDonachiePHSallamAWhich visual acuity measurements define high-quality care for patients with neovascular age-related macular degeneration treated with ranibizumab?Eye (Lond)2013271566423174752
PubMed Web of Science ®Google Scholar
SahaCJonesMPBias in the last observation carried forward method under informative dropoutJ Stat Plan Infer20091392246255
Web of Science ®Google Scholar
DiLoretoDAJrBresslerNMBresslerSBSchachatAPUse of best and final visual acuity outcomes in ophthalmological researchArch Ophthalmol2003121111586159014609916
PubMedGoogle Scholar
rcseng.ac.uk [homepage on the Internet]LondonRoyal College of SurgeonsRCS hails landmark publication of individual surgeons’ outcomes data2013 Available from: http://www.rcseng.ac.uk/news/rcs-hails-landmark-publication-of-individual-surgeons2019-outcomes-dataAccessed June 28, 2013
Google Scholar

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Bilateral visual outcomes and service utilization of patients treated for 3 years with ranibizumab for neovascular age-related macular degeneration

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Bilateral visual outcomes and service utilization of patients treated for 3 years with ranibizumab for neovascular age-related macular degeneration

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date